Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check5 days agoChange DetectedA new revision entry 'Revision: v3.6.3' was added to the site's revision log, while older items including 'Lung cancer', 'related topics:', 'MedlinePlus Genetics', and 'Revision: v3.6.2' were removed.SummaryDifference0.2%

- Check12 days agoChange DetectedAdded Lung cancer and related topics with a MedlinePlus Genetics link to the page's information section. The revision tag was updated to v3.6.2, replacing the previous v3.6.0.SummaryDifference0.2%

- Check19 days agoChange DetectedThe page's MedlinePlus related topics section has had items removed, including Lung cancer and MedlinePlus Genetics, along with the related topics header.SummaryDifference0.1%

- Check26 days agoChange DetectedRecruitment status shows enrollment is closed, and new sections like How to Read a Study Record, Common Questions, How to Join a Study, and related topics have been added to guide users through the study information.SummaryDifference0.5%

- Check33 days agoChange DetectedThe footer now lists Revision: v3.5.5, replacing the previous revision, and several generic links/topics (Lung cancer, related topics, MedlinePlus Genetics) have been removed.SummaryDifference0.2%

- Check40 days agoChange DetectedAdded related topics and links for Lung cancer and MedlinePlus Genetics to the page's related information section, enhancing navigation to disease context and genetics resources.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.